Reviva Pharmaceuticals Holdings, Inc. (RVPH)

RVPH Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14.44	13.48	23.37	18.52	29.69
Cash & Short-Term Investments	14.44	13.48	23.37	18.52	29.69
Cash Growth	7.14%	-42.33%	26.17%	-37.62%	238.89%
Other Current Assets	0.66	1.21	0.33	0.4	1.72
Total Current Assets	15.1	14.68	23.7	18.92	31.4
Other Long-Term Assets	0.82	0.82	-	-	-
Total Assets	15.92	15.5	23.7	18.92	31.4
Accounts Payable	3.01	6.28	3.85	3.52	0.51
Accrued Expenses	3.86	7.86	13.33	6.44	1.84
Short-Term Debt	0.41	0.46	-	-	-
Total Current Liabilities	7.28	14.6	17.18	9.96	2.34
Other Long-Term Liabilities	-	0.09	0.81	0.57	0.37
Total Long-Term Liabilities	-	0.09	0.81	0.57	0.37
Total Liabilities	7.28	14.69	17.98	10.53	2.72
Common Stock	0.01	0	0	0	0
Additional Paid-in Capital	192.77	165.08	140.07	103.49	95.52
Retained Earnings	-184.14	-164.27	-134.35	-95.09	-66.83
Shareholders' Equity	8.65	0.81	5.72	8.39	28.69
Total Liabilities & Equity	15.92	15.5	23.7	18.92	31.4
Total Debt	0.41	0.46	0	0	0
Net Cash (Debt)	14.03	13.02	23.37	18.52	29.69
Net Cash Growth	7.79%	-44.29%	26.17%	-37.62%	238.89%
Net Cash Per Share	3.87	7.71	19.64	18.98	40.14
Book Value	8.65	0.81	5.72	8.39	28.69
Book Value Per Share	2.38	0.48	4.81	8.60	38.79
Tangible Book Value	8.65	0.81	5.72	8.39	28.69
Tangible Book Value Per Share	2.38	0.48	4.81	8.60	38.79

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q